Redwood City, CA, United States of America

Kevin T Mellem

This inventor holds 12 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Revolution Medicines, Inc., Sfunga Therapeutics, Inc., Maze Therapeutics, Inc.. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin T Mellem. Retrieved from https://idiyas.com/inventor/kevin-t-mellem

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 7.8

ph-index = 4

Forward Citations = 38(Granted Patents)

Company Filing History:

8 out of 42

Revolution Medicines, Inc.

patents

3 out of 3

Sfunga Therapeutics, Inc.

patents

1 out of 4

Maze Therapeutics, Inc.

patents

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

SHP2 Inhibitors

GYS1 Inhibitors

mTOR Inhibitors

Pyrazolopyrazines

Imidazopyrazines

Pyridine Compounds

Polycyclic Compounds

Amphotericin B Derivatives

Triazine Compounds

3-Methyl Pyrazines

Allosteric Inhibitors

Chemical Derivatives

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12365688 - Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors (2025-07-22),

2. 11814367 - Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof (2023-11-14),

3. 11739093 - Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors (2023-08-29),

4. 11702411 - Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors (2023-07-18),

5. 11673901 - Polycyclic compounds as allosteric SHP2 inhibitors (2023-06-13),

6. 11673896 - Pyridine compounds as allosteric SHP2 inhibitors (2023-06-13),

7. 11661401 - 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors (2023-05-30),

8. 10980889 - C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors (2021-04-20),

9. 10882883 - Derivatives of amphotericin B (2021-01-05),

10. 10597420 - Derivatives of amphotericin B (2020-03-24),

11. 10590090 - 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors (2020-03-17),

12. 9957290 - Derivatives of amphotericin B (2018-05-01),

Title: Kevin T Mellem: Innovator in Allosteric Inhibitors

Introduction:

Kevin T Mellem is a prominent inventor based in Redwood City, California, known for his significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 12 patents, Mellem has established himself as a key innovator in the development of therapeutic agents targeting various diseases.

Latest Patents:

Among his most recent patents, Kevin Mellem has focused on the development of substituted pyrazolopyrazines, imidazopyrazines, and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors. This innovative work addresses critical problems in the medical field, specifically regarding the inhibition of SHP2, a protein implicated in various diseases. Additionally, he has introduced inhibitors of glycogen synthase 1 (GYS1), outlining methods of preparing these compounds and their applications in treating GYS1-mediated diseases, disorders, or conditions.

Career Highlights:

Throughout his career, Kevin Mellem has collaborated with leading companies in the biotechnology sector. Notably, he has worked with Revolution Medicines, Inc., and Sfunga Therapeutics, Inc., where he has aimed to translate his cutting-edge research into viable therapeutic solutions. His involvement in these organizations underscores his commitment to advancing innovative treatments.

Collaborations:

In his professional journey, Kevin Mellem has collaborated with other notable researchers, including Elena S. Koltun and Adrian L. Gill. These partnerships have provided valuable insights and expertise, further enhancing the impact of his inventions in the scientific community.

Conclusion:

Kevin T Mellem's innovative contributions to medicinal chemistry, particularly in the field of allosteric inhibitors, position him as a leading inventor. His dedication to research and development continues to pave the way for new therapeutic options, making a significant impact on healthcare solutions. Through his work, Mellem exemplifies the spirit of invention and the importance of collaboration in driving forward scientific discovery.

Profile summary based on public USPTO records.